Compositions and methods for treating fibromyalgia
Embodiments of the invention generally relate to supplements for treating fibromyalgia and symptoms associated with fibromyalgia, wherein the nutritional supplement is administered for at least one of following: fatigue, chronic pain, morning stiffness, headaches, and problems with thinking and memory.
1. A method of treating fibromyalgia and fibromyalgia-associated symptoms in a human in need thereof, comprising:
administering an effective amount of a nutritional supplement, consisting essentially of:
about 1 mmol L-arginine; about 1 mmol Oxo-proline;
about 2 mmol L-lysine;
about 1.5 pmol N-acetyl L-cysteine or about 2 pmol L-glutamine;
and about 125 pg Schizonepta (aerial parts) powder, wherein the nutritional supplement is administered for at least one of following: chronic pain, morning stiffness, trouble sleeping, and headaches.
2. The method of claim 1 , wherein the nutritional supplement is orally administered.
3. The method of claim 1 , wherein the nutritional supplement is administered in an amount of about 20-50 g per kg of body weight.
4. The method of claim 1 , wherein the nutritional supplement is in the form of a powder, tablet, capsule, liquid, or wafer.
5. The method of claim 1 , wherein the nutritional supplement is administered once a week or once a month.
6. The method of claim 1 , wherein the nutritional supplement consists essentially of both cysteine and glutamine.
7. A method of treating fibromyalgia and fibromyalgia-associated symptoms in a human in need thereof, comprising:
administering an effective amount of a nutritional supplement to said human, wherein said nutritional supplement consists essentially of:
3.44 mmol L-arginine;
5.30 mmol Oxo-proline;
8.21 mmol L-lysine;
6.13 pmol N-acetyl L-cysteine; and
6.84 pmol L-glutamine, wherein the nutritional supplement is administered for at least one of following: chronic pain, morning stiffness, headaches, and trouble sleeping.
8. The method of claim 7 , wherein the nutritional supplement further comprises 0.50 mg Schizonepta (aerial parts) powder.
9. The method of claim 7 , wherein the nutritional supplement consists of 725.50 mg L-arginine HCl; 683.70 mg L-pyroglutamic acid; 1499.30 mg L-lysine HCl; 1.00 mg N-acetyl L-cysteine USP; 1.00 mg L-glutamine; and 0.50 mg Schizonepta (aerial parts) powder.
10. The method of claim 1 , wherein the nutritional supplement is orally administered.
11. The method of claim 1 , wherein the nutritional supplement is administered in an amount of about 20-50 g per kg of body weight.
12. The method of claim 1 , wherein the nutritional supplement is in the form of a powder, tablet, capsule, liquid, or wafer.
13. The method of claim 7 , wherein the nutritional supplement is administered once a week or once a month.
14. The method of claim 7 , wherein the nutritional supplement is administered one to three times daily.
15. The method of claim 7 , wherein the nutritional supplement is administered on an empty stomach.